About: Cethromycin

An Entity of Type: organisation, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Cethromycin, trade name Restanza (initially known as ABT-773) is a ketolide antibiotic undergoing research for the treatment of community acquired pneumonia (CAP) and for the prevention of post-exposure inhalational anthrax, and was given an "orphan drug" status for this indication. Originally discovered and developed by Abbott, it was acquired by Advanced Life Sciences Inc. for further development. On October 1, 2008 Advanced Life Sciences submitted a New Drug Application (NDA) to Food and Drug Administration (FDA) for cethromycin to treat mild-to-moderate community acquired pneumonia.

Property	Value
dbo:abstract	سيثرومايسين اسمه التجاري (بالإنجليزية: Restanza)‏ (المعروف في البداية باسم ABT-773) هو مضاد حيوي للكيتوليد يخضع لأبحاث لعلاج الالتهاب الرئوي المكتسب من المجتمع (CAP). الوقاية من الجمرة الخبيثة الاستنشاقية بعد التعرض، وتم إعطاؤها حالة «عقار يتيم» لهذا المؤشر. تم اكتشافها وتطويرها في الأصل من قبل شركة Abbott. (ar) Cethromycin ist ein Glycosid und Antibiotikum aus der Gruppe der . Es inhibiert die Proteinbiosynthese von Bakterien. Cethromycin befindet sich derzeit in klinischen Phase-III-Studien (Abbott) und soll gegen Infektionen des Respirationstraktes eingesetzt werden, z. B. gegen Streptococcus pneumoniae. (de) Cethromycin, trade name Restanza (initially known as ABT-773) is a ketolide antibiotic undergoing research for the treatment of community acquired pneumonia (CAP) and for the prevention of post-exposure inhalational anthrax, and was given an "orphan drug" status for this indication. Originally discovered and developed by Abbott, it was acquired by Advanced Life Sciences Inc. for further development. On October 1, 2008 Advanced Life Sciences submitted a New Drug Application (NDA) to Food and Drug Administration (FDA) for cethromycin to treat mild-to-moderate community acquired pneumonia. On December 3, 2008 Advanced Life Sciences announced that this New Drug Application has been accepted for filing by the FDA. In June 2009, an FDA Anti-Infective Drugs Advisory Committee review found insufficient evidence for cethromycin efficacy in treatment of community acquired pneumonia, as the Phase 3 clinical trial followed standards that were updated after the clinical trial but three months prior to review. The committee did, however, find the drug safe to use. (en) セスロマイシン（Cethromycin）とは、マクロライド系の抗菌薬の中でもケトライドに分類される、抗菌薬の1種である。 (ja)
dbo:bioavailability	60.000000 (xsd:float)
dbo:casNumber	205110-48-1
dbo:chEBI	29506
dbo:chEMBL	365528
dbo:fdaUniiCode	J0086219X6
dbo:kegg	D02391
dbo:pubchem	5282045
dbo:thumbnail	wiki-commons:Special:FilePath/Cethromycin1.svg?width=300
dbo:wikiPageExternalLink	http://aac.asm.org/cgi/content/full/48/4/1096
dbo:wikiPageID	16911143 (xsd:integer)
dbo:wikiPageLength	6415 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1089631412 (xsd:integer)
dbo:wikiPageWikiLink	dbr:New_Drug_Application dbr:Antibiotic dbr:Orphan_drug dbr:Anthrax dbr:Liver dbr:Clinical_trial dbr:Ketolide dbr:Abbott_Laboratories dbr:Food_and_Drug_Administration dbc:Quinolines dbc:Ketolide_antibiotics dbr:Community_acquired_pneumonia
dbp:atcPrefix	none (en)
dbp:bioavailability	Between 35.8 and 60% in animal studies. (en)
dbp:c	42 (xsd:integer)
dbp:casNumber	205110 (xsd:integer)
dbp:chebi	29506 (xsd:integer)
dbp:chembl	365528 (xsd:integer)
dbp:chemspiderid	23258189 (xsd:integer)
dbp:eliminationHalfLife	1.600000 (xsd:double)
dbp:excretion	7 (xsd:integer)
dbp:h	59 (xsd:integer)
dbp:iupacName	-8 (xsd:integer)
dbp:kegg	D02391 (en)
dbp:legalUsComment	dbr:Clinical_trial
dbp:meltingHigh	213 (xsd:integer)
dbp:meltingPoint	211 (xsd:integer)
dbp:metabolism	dbr:Liver
dbp:n	3 (xsd:integer)
dbp:o	10 (xsd:integer)
dbp:pubchem	5282045 (xsd:integer)
dbp:routesOfAdministration	Oral (en)
dbp:smiles	CC[C@@H]1[C@@]2C (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	PENDGIOBPJLVBT-HMMOOPTJSA-N (en)
dbp:unii	J0086219X6 (en)
dbp:verifiedfields	changed (en)
dbp:verifiedrevid	445236160 (xsd:integer)
dbp:watchedfields	changed (en)
dbp:wikiPageUsesTemplate	dbt:Drugbox dbt:Reflist dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Ebicite dbt:Fdacite dbt:Keggcite dbt:Stdinchicite dbt:Macrolides,_lincosamides_and_streptogramins
dcterms:subject	dbc:Quinolines dbc:Ketolide_antibiotics
gold:hypernym	dbr:Research
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatCarbamates yago:WikicatMolecularFormulas yago:Abstraction100002137 yago:Acetal114710805 yago:AliphaticCompound114601294 yago:Alkene114713120 yago:Carbamate114792281 yago:Chemical114806838 yago:Communication100033020 yago:Compound114818238 yago:Element114840755 yago:Formula106816935 yago:Glycoside114887305 yago:Ketone114926294 yago:Material114580897 yago:Matter100020827 yago:Message106598915 yago:MolecularFormula106817173 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Quintessence114847103 yago:Relation100031921 yago:WikicatGlycosides yago:WikicatKetones dbo:Drug dbo:Organisation yago:Salt115010703 yago:Statement106722453 yago:Substance100019613 yago:WikicatAcetals yago:WikicatAlkenes yago:WikicatEthers umbel-rc:DrugProduct
rdfs:comment	سيثرومايسين اسمه التجاري (بالإنجليزية: Restanza)‏ (المعروف في البداية باسم ABT-773) هو مضاد حيوي للكيتوليد يخضع لأبحاث لعلاج الالتهاب الرئوي المكتسب من المجتمع (CAP). الوقاية من الجمرة الخبيثة الاستنشاقية بعد التعرض، وتم إعطاؤها حالة «عقار يتيم» لهذا المؤشر. تم اكتشافها وتطويرها في الأصل من قبل شركة Abbott. (ar) Cethromycin ist ein Glycosid und Antibiotikum aus der Gruppe der . Es inhibiert die Proteinbiosynthese von Bakterien. Cethromycin befindet sich derzeit in klinischen Phase-III-Studien (Abbott) und soll gegen Infektionen des Respirationstraktes eingesetzt werden, z. B. gegen Streptococcus pneumoniae. (de) セスロマイシン（Cethromycin）とは、マクロライド系の抗菌薬の中でもケトライドに分類される、抗菌薬の1種である。 (ja) Cethromycin, trade name Restanza (initially known as ABT-773) is a ketolide antibiotic undergoing research for the treatment of community acquired pneumonia (CAP) and for the prevention of post-exposure inhalational anthrax, and was given an "orphan drug" status for this indication. Originally discovered and developed by Abbott, it was acquired by Advanced Life Sciences Inc. for further development. On October 1, 2008 Advanced Life Sciences submitted a New Drug Application (NDA) to Food and Drug Administration (FDA) for cethromycin to treat mild-to-moderate community acquired pneumonia. (en)
rdfs:label	سيثرومايسين (ar) Cethromycin (de) Cethromycin (en) セスロマイシン (ja)
owl:sameAs	freebase:Cethromycin yago-res:Cethromycin wikidata:Cethromycin dbpedia-ar:Cethromycin dbpedia-de:Cethromycin dbpedia-fa:Cethromycin dbpedia-ja:Cethromycin dbpedia-sh:Cethromycin dbpedia-sr:Cethromycin dbpedia-vi:Cethromycin https://global.dbpedia.org/id/8Rte
prov:wasDerivedFrom	wikipedia-en:Cethromycin?oldid=1089631412&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Cethromycin1.svg
foaf:isPrimaryTopicOf	wikipedia-en:Cethromycin
is dbo:wikiPageRedirects of	dbr:C42H59N3O10
is dbo:wikiPageWikiLink of	dbr:Ketolide dbr:Macrolide dbr:C42H59N3O10 dbr:Erythromycin dbr:List_of_drugs:_Cb–Ce
is foaf:primaryTopic of	wikipedia-en:Cethromycin

This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License